Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma

Abstract Background Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). Methods Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomat...

Full description

Bibliographic Details
Main Authors: Moire Cuncannon, Matthew Wong, Dasantha Jayamanne, Linxin Guo, Nicola Cove, Helen Wheeler, Michael Back
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Cancer
Subjects:
Glioblastoma
Bevacizumab
Salvage
Survival
Online Access:http://link.springer.com/article/10.1186/s12885-019-5678-1

Internet

http://link.springer.com/article/10.1186/s12885-019-5678-1

Similar Items